Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics (DE:1S9)
BERLIN:1S9
RESEARCH TOOLSreports
Seres Therapeutics (1S9) Stock Price & Analysis
1 Followers
1S9 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.53 - €7.00
Previous Close€0.58
Volume0.00
Average Volume (3M)2.03K
Market Cap
€107.15M
Enterprise Value€187.75M
Total Cash (Recent Filing)$127.97M
Total Debt (Recent Filing)$213.94M
Price to Earnings (P/E)N/A
Beta0.43
Next Earnings
May 01, 2024EPS Estimate
-€0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding151,009,462
10 Day Avg. Volume0
30 Day Avg. Volume2,028
Standard Deviation0.20
R-Squared0.01
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)-2.56
Price to Sales (P/S)34.91
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.49
Enterprise Value/Gross Profit1.49
Enterprise Value/Ebitda-3.35
Forecast
1Y Price Target
€4.39Price Target Upside535.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Seres Therapeutics News
PremiumCompany Announcements
A New Cause for Concern: Seres Therapeutics Inc. Adds a New Supply Chain Risk
PremiumCompany Announcements
Seres Therapeutics Announces 2024 Virtual Stockholders MeetingBulls Say, Bears Say
Bulls Say
Insurance CoverageReimbursement coverage for the product is expanding, with a majority of patients now enjoying insurance coverage.
Management OutlookManagement expresses optimism for the product's continued growth.
Product LaunchThe launch is progressing ahead of projections with increasing patient starts from prescription enrollment forms.
Bears Say
Financial PerformanceCompany's share of the net loss was significant in the reported fiscal year.
Future OutlookLimited visibility into potential growth opportunities for their pipeline beyond Vowst.
Product SalesVowst sales in recurrent CDI of $10.4mn was lower than expectations.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.03% Other Institutional Investors
99.97% Public Companies and
Individual Investors
1S9 FAQ
What was Seres Therapeutics’s price range in the past 12 months?
Seres Therapeutics lowest stock price was €0.53 and its highest was €7.00 in the past 12 months.
What is Seres Therapeutics’s market cap?
Currently, no data Available
When is Seres Therapeutics’s upcoming earnings report date?
Seres Therapeutics’s upcoming earnings report date is May 01, 2024 which is in 5 days.
How were Seres Therapeutics’s earnings last quarter?
Seres Therapeutics released its earnings results on Mar 05, 2024. The company reported -€0.291 earnings per share for the quarter, beating the consensus estimate of -€0.466 by €0.175.
Is Seres Therapeutics overvalued?
According to Wall Street analysts Seres Therapeutics’s price is currently Undervalued.
Does Seres Therapeutics pay dividends?
Seres Therapeutics does not currently pay dividends.
What is Seres Therapeutics’s EPS estimate?
Seres Therapeutics’s EPS estimate is -€0.32.
How many shares outstanding does Seres Therapeutics have?
Currently, no data Available
What happened to Seres Therapeutics’s price movement after its last earnings report?
Seres Therapeutics reported an EPS of -€0.291 in its last earnings report, beating expectations of -€0.466. Following the earnings report the stock price went down -11.468%.
Which hedge fund is a major shareholder of Seres Therapeutics?
Among the largest hedge funds holding Seres Therapeutics’s share is Flagship Pioneering Inc.. It holds Seres Therapeutics’s shares valued at 32M.
---
Seres Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.39 (535.23% Upside)
€4.39 (535.23% Upside)
Blogger Sentiment
Bullish
DE:1S9 Sentiment 66%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.81%
Trailing 12-Months
Company Description
Seres Therapeutics
Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
---
1S9 Earnings Call
Q4 2024
0:00 / 0:00
---
1S9 Stock 12 Months Forecast
Average Price Target
€4.39
▲(535.23% Upside)
Technical Analysis
Seres Therapeutics
―
Amicus
―
FibroGen
―
Karyopharm Therapeutics
―
Arrowhead Pharmaceuticals
―
Best Analysts Covering 1S9
1 Year
1 Year Success Rate
12/20 ratings generated profit
1 Year Average Return
+124.74%
reiterated a sell rating 3 months ago
Copying Chris Shibutani's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +124.74% per trade.
---